HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Douglas Millar Selected Research

HHS 5

3/2016A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Douglas Millar Research Topics

Disease

1Breast Neoplasms (Breast Cancer)
03/2016
1Sudden Infant Death (SID)
03/2016
1Neoplasms (Cancer)
01/2008

Drug/Important Bio-Agent (IBA)

1Trastuzumab (Herceptin)FDA Link
03/2016
1HHS 5IBA
03/2016
1DNA (Deoxyribonucleic Acid)IBA
01/2008
1Bovine Serum AlbuminIBA
01/2008